Cargando…
A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS)
OBJECTIVE: Up to 87% of uterine leiomyosarcomas have estrogen receptor positivity. There are no effective adjuvant therapies for LMS. The objective of this study was to determine the efficacy of letrozole in patients with newly diagnosed uterine leiomyosarcoma (uLMS). The primary endpoint of this st...
Autores principales: | Slomovitz, Brian M., Taub, Michael C., Huang, Marilyn, Levenback, Charles, Coleman, Robert L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260388/ https://www.ncbi.nlm.nih.gov/pubmed/30519622 http://dx.doi.org/10.1016/j.gore.2018.11.001 |
Ejemplares similares
-
Effect of 2-methoxyestradiol on SK-LMS-1 uterine leiomyosarcoma cells
por: Lee, Ji-Sun, et al.
Publicado: (2017) -
Neutrophil-to-Lymphocyte Ratio (NLR) for Preoperative Differentiation between Uterine Leiomyosarcoma (LMS) and Uterine Leiomyoma: A Case-Controlled Study
por: Srisutha, Phitsinee, et al.
Publicado: (2023) -
Ulm design : the morality of objects = Hochschule für Gestaltung Ulm, 1953-1968 /
Publicado: (1991) -
Leiomyosarcoma with osteoclast‐like (LMS‐OGC) giant cells the breast: A report of a rare case
por: Xu, Zhonghai, et al.
Publicado: (2019) -
Uterine Leiomyosarcoma
por: Byar, Katherine L., et al.
Publicado: (2022)